PAPER
SEARCH RESULTS
341218 RESULTS
PAPER Hasan AH, Abid MA
Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management.
Cureus. 2024 Oct;16(10):e71131. Epub 2024 Oct 9 PubMed.PAPER Tandon R
Finally, a non-dopaminergic antipsychotic (xanomeline-trospium) for treatment of schizophrenia: Significance and learnings.
Asian J Psychiatr. 2024 Nov 19;102:104320. Epub 2024 Nov 19 PubMed.PAPER Leber A, Ramachandra R, Ceban F, Kwan AT, Rhee TG, Wu J, Cao B, Jawad MY, Teopiz KM, Ho R, Le GH, Ramachandra D, McIntyre RS
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review.
Expert Opin Pharmacother. 2024 Mar;25(4):467-476. Epub 2024 Mar 27 PubMed.PAPER Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
J Clin Psychiatry. 2022 May 11;83(3) PubMed.PAPER Horan WP, Targum SD, Claxton A, Kaul I, Yohn SE, Marder SR, Miller AC, Brannan SK
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
Schizophr Res. 2024 Sep 10;274:57-65. Epub 2024 Sep 10 PubMed.PAPER Kaul I, Sawchak S, Claxton A, Sauder C, Hassman HH, Kakar R, Walling DP, Citrome L, Zhu H, Miller AC, Brannan SK
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Schizophrenia (Heidelb). 2024 Nov 2;10(1):102. PubMed.PAPER Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
JAMA Psychiatry. 2024 Aug 1;81(8):749-756. PubMed.PAPER Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet. 2024 Jan 13;403(10422):160-170. Epub 2023 Dec 14 PubMed.PAPER Correll CU, Angelov AS, Miller AC, Weiden PJ, Brannan SK
Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.
Schizophrenia (Heidelb). 2022 Dec 3;8(1):109. PubMed.Gayle Wooten
Hot Springs Village, United States
Emily Blackburn
Anadel Espinosa
United Kingdom
Troy Allen
Mount Clare, United States
PAPER Williams VJ, Trane R, Sicinski K, Herd P, Engelman M, Asthana S
Midlife and late-life environmental exposures on dementia risk in the Wisconsin Longitudinal Study: The modifying effects of ApoE.
Alzheimers Dement. 2024 Nov 22; Epub 2024 Nov 22 PubMed.Current Filters
No filters selected